Intimitation under Regulation 47 for the publication of quarter and half year ended 30th September 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Boston Bio Systems Limited has submitted copies of newspaper advertisements published in Financial Express (English and Gujarati) on 15 November 2025, in compliance with SEBI Regulation 47. The advertisements contain the company's standalone unaudited financial results for the quarter and half year ended 30 September 2025, which were approved by the Board of Directors on 14 November 2025. Key numbers: H1 FY26 total income from operations was Rs. 42.52 lakhs with a profit after tax of Rs. 7.95 lakhs (EPS of Rs. 0.11), a turnaround from a loss of Rs. 0.50 lakh in H1 FY25. For Q2 FY26 standalone, total income was Rs. 24.47 lakhs and profit after tax was Rs. 3.94 lakhs (EPS Rs. 0.06). However, the full year FY25 (audited) had closed with a loss of Rs. 54.73 lakhs and negative EPS of Rs. 0.78. Equity share capital remains Rs. 700.22 lakhs.
This is a routine regulatory compliance filing (newspaper publication of quarterly results) and does not directly affect shareholders. The Q2/H1 FY26 results show a swing to profitability compared to the prior year period, but the stock remains a small-cap with a negative full-year FY25 outcome, so the operational turnaround needs to be sustained over coming quarters to meaningfully impact the share price.